KK3A Stock Overview
A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Cytokinetics, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.60 |
| 52 Week High | US$99.50 |
| 52 Week Low | US$28.20 |
| Beta | 0.78 |
| 11 Month Change | -2.92% |
| 3 Month Change | -8.63% |
| 1 Year Change | 59.59% |
| 33 Year Change | 31.64% |
| 5 Year Change | 445.03% |
| Change since IPO | 91.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| KK3A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -0.7% | -0.02% |
| 1Y | 59.6% | -17.2% | 8.2% |
Return vs Industry: KK3A exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: KK3A exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| KK3A volatility | |
|---|---|
| KK3A Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: KK3A has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: KK3A's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 423 | Robert Blum | www.cytokinetics.com |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company’s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
Cytokinetics, Incorporated Fundamentals Summary
| KK3A fundamental statistics | |
|---|---|
| Market cap | €5.56b |
| Earnings (TTM) | -€553.52m |
| Revenue (TTM) | €3.09m |
1,800x
P/S Ratio-10.1x
P/E RatioIs KK3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KK3A income statement (TTM) | |
|---|---|
| Revenue | US$3.22m |
| Cost of Revenue | US$330.76m |
| Gross Profit | -US$327.54m |
| Other Expenses | US$248.87m |
| Earnings | -US$576.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.88 |
| Gross Margin | -10,175.09% |
| Net Profit Margin | -17,906.24% |
| Debt/Equity Ratio | -5,568.4% |
How did KK3A perform over the long term?
See historical performance and comparison